- Home
- PRTA vs CSTL Comparison
PRTA vs CSTL Comparison
Compare PRTA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- CSTL
- Stock Information
- Founded
- PRTA 2012
- CSTL 2007
- Country
- PRTA Ireland
- CSTL United States
- Employees
- PRTA N/A
- CSTL N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- PRTA Health Care
- CSTL Health Care
- Exchange
- PRTA Nasdaq
- CSTL Nasdaq
- Market Cap
- PRTA 802.8M
- CSTL 946.1M
- IPO Year
- PRTA N/A
- CSTL 2019
- Fundamental
- Price
- PRTA $14.01
- CSTL $28.10
- Analyst Decision
- PRTA Buy
- CSTL Strong Buy
- Analyst Count
- PRTA 7
- CSTL 7
- Target Price
- PRTA $57.67
- CSTL $37.57
- AVG Volume (30 Days)
- PRTA 476.3K
- CSTL 457.0K
- Earning Date
- PRTA 11-12-2024
- CSTL 11-04-2024
- Dividend Yield
- PRTA N/A
- CSTL N/A
- EPS Growth
- PRTA N/A
- CSTL N/A
- EPS
- PRTA N/A
- CSTL 0.21
- Revenue
- PRTA $133,350,000.00
- CSTL $311,878,000.00
- Revenue This Year
- PRTA $60.63
- CSTL $49.05
- Revenue Next Year
- PRTA N/A
- CSTL N/A
- P/E Ratio
- PRTA N/A
- CSTL $133.58
- Revenue Growth
- PRTA N/A
- CSTL 62.43
- 52 Week Low
- PRTA $14.00
- CSTL $16.97
- 52 Week High
- PRTA $41.55
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- PRTA 31.91
- CSTL 35.44
- Support Level
- PRTA $17.27
- CSTL $30.95
- Resistance Level
- PRTA $18.60
- CSTL $34.64
- Average True Range (ATR)
- PRTA 1.11
- CSTL 2.15
- MACD
- PRTA -0.15
- CSTL -0.56
- Stochastic Oscillator
- PRTA 0.20
- CSTL 1.02
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.